secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001564590-22-037486
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke reports positive interim Phase 1/2a data for STK-001 in Dravet syndrome; 55% median seizure reduction at 45mg
--------------------------------------------------------------------------------

- STK-001 up to 45mg well-tolerated; 55% median reduction in convulsive seizures with three doses of 45mg (n=6).
- 74% of patients (20/27) experienced reduction in seizure frequency after three doses of STK-001.
- Cash of $252.2M as of Sep 30, 2022 expected to fund operations into 2025; Q3 net loss $26.1M ($0.66/share).
- FDA granted Rare Pediatric Disease Designation for STK-001 in Dravet syndrome in October 2022.
- Planned data updates on multiple doses of 45mg and 70mg in 2023; AES presentation Dec 2-6.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000156459022037486/0001564590-22-037486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000156459022037486/stok-8k_20221114.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-037486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer